Pfizer's Icagen buyout draws investor lawsuit

Law firms began circling Pfizer's $6-a-share buyout deal for Icagen hours after the acquisition left shareholders scrambling to deal with a price that fell well below their expectations. Now Michael Rauscher has emerged as the first investor to get to the courts, filing a claim that the buyout deal--which cost Pfizer close to $50 million for the shares it didn't already own--significantly undervalued the company. More investor suits are expected. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.